Advertisement

FDA investigators cite 23 process- and procedure-related "observations" following an inspection of Hospira's India-based facility.

FDA complete Hospira facility inspection

Hospira (NYSE:HSP) has nearly 2 dozen items to address following another FDA inspection at an India-based drug-manufacturing facility.

The FDA completed its latest Hospira site inspection with 23 cited "observations" regarding processes and procedures at the Irungattukottai, India, plant, according to regulatory filings. Hospira officials estimated that the FDA's Form 483 citations wouldn't impact its financial guidance for 2013.

Advertisement
Advertisement